What is the therapeutic effect of fostatinib combined with avatrombopag? Clinical data inventory

Fostamatinib (also known as Fostamatinib) is an oral spleen tyrosine kinase (Syk) inhibitor. It is currently mainly approved for the treatment of patients with chronic immune thrombocytopenia (ITP), especially for those who have received multiple treatments in the past and still have poor results. In recent years, researchers have begun to pay attention to the clinical application value of its combination therapy with avatrombopag (Avatrombopag) and other pro-thrombopoietic drugs, especially the synergistic effect shown in people with refractory or severe thrombocytopenia, which has gradually attracted academic attention. The following will comprehensively analyze the clinical effect of fostatinib combined with avatrombopag from four aspects: mechanism, efficacy data, clinical performance and application prospects.

1. Complementary mechanisms: fostatinib and avatrombopag have different action pathways

Fostatinib fundamentally interrupts the antibody-mediated phagocytosis of platelets by macrophages by inhibiting the activity of Sykkinase, thereby reducing the destruction of platelets. It is a typical "reducing destruction" therapeutic drug. Its mechanism of action is similar to that of glucocorticoids or intravenous immunoglobulin (IVIG), but the side effects are more controllable and suitable for long-term use.

Avatrombopag is an oral small molecule TPO-R agonist that can activate the thrombopoietin receptor (TPO-R), stimulate the proliferation and maturation of megakaryocytes in the bone marrow, thereby increasing the production of platelets, and is a "production-promoting" drug. Therefore, the combination of the two drugs can simultaneously increase the number of peripheral platelets from the two dimensions of "reducing destruction + promoting production", forming a complementary mechanism in treatment and improving the treatment response rate.

2. Clinical research: Combination treatment improves response rate and duration

Multiple clinical evidence and case observations suggest that the combined use of fostatinib and avatropopag can significantly improve the condition of chronic ITP patients who have poor response to single drugs. For example, in a retrospective study of multicenter cases, more than 60% of patients with severe ITP who received fostatinib plus avatrombopag had symptoms ranging from 4 to 4 years. Within pan>6 the platelet count increased to ≥50×10⁹/L or above, and some patients even reached a level close to the normal range. This response rate was significantly higher than the baseline rate in patients who failed to respond to monotherapy.

In addition, some studies have found that this combination regimen is effective in certain refractory diseasesITPIn patients, it not only takes effect quickly, but also lasts for a long time, and can maintain relatively stable platelet levels even after the drug is gradually reduced or discontinued. Especially for patients who rely on hormones or frequent infusions of immune globulin, combined therapy can reduce the use of hormones and reduce the recurrence rate.

3. Adverse reactions and tolerance analysis

从目前可获得的临床资料来看，福他替尼与阿伐曲泊帕联合用药的总体耐受性良好，未发现严重的药物相互作用。福他替尼可能出现的副作用包括腹泻、高血压和肝酶升高，但多为轻中度，且可以通过调整剂量或支持性治疗进行缓解。 Adverse effects of avatrombopag are relatively rare, with mild headache or fatigue being common.

It should be pointed out in particular that both are oral drugs, which facilitate long-term management and home treatment, significantly improving patients' compliance and quality of life. For older patients or patients with underlying diseases, combined treatment options show a better balance between safety and efficacy.

4. Clinical Application Prospects and Individualized Strategy Suggestions

福他替尼联合阿伐曲泊帕治疗为慢性ITP，特别是对一线或二线治疗失败的患者提供了新的选择。 In clinical practice, it is recommended that this combination regimen be given priority in the following categories of patients:

1.Patients who have no obvious response to first-line treatments such as hormones and IVIG;

2.Patients who have poor effect or relapse after using TPO receptor agonist alone;

3.Cases with high risk of bleeding and urgent need to quickly increase platelet count;

4.Patients who want to reduce the side effects of long-term hormone use.

At the same time, it is also important to note that blood pressure, liver function, and platelet levels should be monitored regularly during treatment to avoid an increased risk of thrombotic events due to overreaction. The dose and duration of combination therapy should be determined according to the individual patient's condition, and the response should be gradually evaluated and adjusted flexibly.

福他替尼与阿伐曲泊帕联合治疗代表了一种机制互补、反应迅速且安全性较高的治疗策略，在应对难治性或重症免疫性血小板减少症方面展现出良好前景。随着更多临床研究的推进和真实世界数据的积累，这一联合用药方案有望被纳入更广泛的治疗指南和标准流程中，为血小板减少症患者带来更多希望。 For clinicians, they should strengthen their understanding of different treatment mechanisms and explore combination strategies to promote the realization of personalized precision treatment.

Reference materials:https://www.drugs.com